Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01015820 · ClinicalTrials.gov registry record · NA

Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer

A NA study, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
37
Enrollment target

NCT01015820: Completed NA study, sponsored by Mayo Clinic.

NCT01015820 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01015820, a NA study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
37 participants
Enrollment target

Study Summary

Pancreatic cancer is the fourth leading cause of cancer death in the United States and is associated with a poor prognosis. The average life expectancy after diagnosis is approximately 5 to 8 months. At present, successful surgical resection is the only curative therapy that can improve long-term survival. However, it can be achieved only when a tumor is detected at an early stage. Unfortunately, due to non-specific symptoms associated with pancreatic cancer, it is commonly detected in the later stages of the disease. The investigators hypothesized that pancreatic cancer could be detected by measuring the changes in the early increase in blood supply (EIBS) found in the surrounding normal-appearing duodenal tissue. The investigators tested a device called Four-dimensional Elastic Light-Scattering Fingerprinting (4D-ELF). The device used in this study is considered investigational, which means it has either not been approved by the Food and Drug Administration (FDA) for routine clinical use or for the use described in this study. However the FDA allowed the use of this device in this research study.

Interventions

  • PROCEDURE EGD with EUS
  • DEVICE 4D-ELF

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2010-06
Est. Completion 2012-10
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT01015820

The ClinicalTrials.gov registry entry for NCT01015820 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which EGD with EUS is the first listed.

NCT01015820 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01015820 about?

NCT01015820 is a clinical study titled "Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer". Pancreatic cancer is the fourth leading cause of cancer death in the United States and is associated with a poor prognosis. The average life expectancy after diagnosis is approximately 5 to 8 months. At present, successful surgical resection is the only curative therapy that can improve long-term su...

What is the current status of trial NCT01015820?

This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2010-06. Estimated completion is 2012-10.

What interventions are being tested in trial NCT01015820?

The interventions under investigation include: EGD with EUS (PROCEDURE), 4D-ELF (DEVICE).

Who is sponsoring clinical trial NCT01015820?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.